Eva Kerby, MD
Dermatology · New York, NYNPI 1336526581
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,398 of the $3,345 with a category attached, or 71.7%. 7 manufacturers reported payments, led by Johnson & Johnson at 42.7% of the total. Reporting peaked in 2024 at $1,633 and has fallen 90.6% since, to $154 in 2025.
Across 15 payments — averaging $223.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$299
- AbbVie$216
- Galderma Laboratories, L.p.$107
- Bristol Myers Squibb$61
- plus $50 from 1 others
What the payments were for
- Consulting fees$2,39872%
- Food & beverage$94728%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $1,430 |
| Sanofi | 3 | $1,184 |
| Regeneron Healthcare Solutions, Inc. | 5 | $299 |
| AbbVie(2 entities) | 2 | $216 |
| Galderma Laboratories, L.p. | 1 | $107 |
| Bristol Myers Squibb | 1 | $61 |
| Novartis | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,345 in reported general payments places this provider in the 55th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $220,302 |
| Dupixent SyringeDupilumab | 26 | $95,698 |
| Tacrolimus | 73 | $10,781 |
| Clobetasol Propionate | 148 | $6,817 |
| Fluocinonide | 77 | $3,375 |
| Ketoconazole | 123 | $2,411 |
| Halobetasol Propionate | 30 | $2,361 |
| Triamcinolone Acetonide | 169 | $2,158 |
| Clindamycin Phosphate | 40 | $1,785 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 22 | $1,301 |
| Minoxidil | 60 | $989 |
| Tretinoin | 16 | $884 |
| Metronidazole | 11 | $590 |
| Finasteride | 30 | $515 |
| ValacyclovirValacyclovir Hcl | 12 | $285 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.